uploads///Part  Graph

IBB Returns to Positive: How Did Its Holdings Perform?


May. 3 2016, Published 1:12 p.m. ET

Reviewing IBB

The markets gained on May 1, 2016. The Dow Jones Industrial Average gained ~0.7% but still closed below 18,000. The iShares NASDAQ Biotechnology ETF (IBB) followed the market trend and gained 1.1% after a five-day losing streak, a positive beginning for May. IBB gained 2.7% during April. IBB outperformed the SPDR S&P 500 ETF (SPY), which rose by 0.8% on May 2, 2016.

The above chart gives information about the prices, returns at various intervals, 12-month target prices, and moving average prices of IBB, SPY, and a few holdings of IBB. The iShares NASDAQ Biotechnology ETF (IBB) closed at $270.94 and was trading below its 20-day moving average. Year-to-date, IBB is down by 19.9%. Approximately 1.9 million shares were traded, against the three-month average trading volume of ~2.4 million shares per day.

Article continues below advertisement

Top movers of the day

Sarepta Therapeutics (SRPT), NewLink Genetics (NLNK), and MannKind (MNKD) were the top gainers on May 2, 2016, with returns of 26.3%, 8.7%, and 7.4%, respectively. Sarepta Therapeutics moved up as the stock was upgraded to “outperform” by Oppenheimer, raising the target price of the stock to $60. This represents an upside of more than 322%. Last week, the FDA rejected eteplirsen for the treatment of Duchenne’s muscular dystrophy.

Sarepta Therapeutics closed at $17.92 and was trading below the 20-day moving average price. Year-to-date, the stock is down by 53.6%. Though Oppenheimer raised the target, the median analyst estimated target price is $10. Four analysts have recommended to “buy,” five analysts have recommended to “hold,” and five analysts have recommended to “sell.” Sarepta has a book value of $4.17 per share. With its current price, the stock is trading at a price-to-book value of 4.3x. Sarepta has a weight of ~0.1% in IBB’s portfolio.


More From Market Realist